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Background: The adipocyte-derived hormone leptin plays a key role in the regulation of appetite and body weight.
Recent studies have suggested that leptin is also involved in the pathogenesis of obesity-related atherosclerosis and
cardiovascular disease. In this study, we investigated the association of plasma leptin levels with vascular endothelial
function in lean and overweight patients with type 2 diabetes.
Methods: One hundred seventy-one type 2 diabetic patients, of which 85 were overweight (body mass index
(BMI) ≥ 25 kg/m2), were enrolled in this cross-sectional study. Plasma leptin concentrations were measured by
enzyme-linked immunosorbent assay. Flow-mediated dilatation (FMD) of the brachial artery was measured to
evaluate vascular endothelial function using ultrasound.
Results: No significant difference in FMD was found between the lean and overweight groups (7.0 ± 3.8% and
6.5 ± 3.6%, respectively; p = 0.354). FMD was negatively correlated with age (r = −0.371, p < 0.001) and serum
creatinine levels (r = −0.236, p = 0.030), but positively correlated with BMI (r = 0.330, p = 0.002) and plasma leptin
levels (r = 0.290, p = 0.007) in the overweight group. FMD was not associated with any parameters in the lean group.
Multiple regression analysis including possible atherosclerotic risk factors revealed that the plasma leptin level
(β = 0.427, p = 0.013) was independently associated with FMD in the overweight group (R2 = 0.310, p = 0.025),
but not the lean group.
Conclusion: Plasma leptin levels are associated with vascular endothelial function in overweight patients with
type 2 diabetes.
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Obesity is a serious health problem worldwide and is
associated with established cardiovascular risk factors
including hypertension, dyslipidemia, insulin resistance,
and diabetes [1]. Adipose tissue exerts endocrine and
immune functions by releasing bioactive mediators and
adipocytokines such as leptin, adiponectin, resistin, tumor
necrosis factor-α, interleukin-6, and monocyte chemotac-
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stated.identified and has been extensively investigated. Leptin
is produced predominantly by adipose tissue and plays
a pivotal role in the regulation of appetite and body
weight. Plasma leptin levels are markedly elevated in obese
individuals, and leptin receptors are widely distributed
in peripheral tissue including the cardiovascular system
[3]. Therefore, hyperleptinemia may be one potential
mechanism linking obesity to atherosclerotic cardiovascular
disease. Recent in vitro and in vivo studies have indicated
that, in addition to its major roles in energy metabolism,
leptin is also involved in the pathophysiology of athero-
sclerosis [1,2,4]. Moreover, several clinical studies havel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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predictor of incident coronary artery disease [5,6].
The integrated effect of leptin on vascular endothelial
function, a key factor for the initiation and development
of atherosclerotic vascular damage [7], remains to be elu-
cidated, since contradictory findings have been reported
from experimental and clinical studies. For example, leptin
was found to induce endothelium-dependent vascular
relaxation by stimulating nitric oxide (NO) in studies
using isolated aortic rings of rats [8,9]. Leptin infusion
also caused vasodilatation of the brachial artery [10]
and coronary artery [11] in non-obese, healthy human
subjects. Nonetheless, in pathological conditions such
as obesity or metabolic syndrome (MetS), resistance to
leptin’s vasodilatory effect has been observed in both
animal [12-14] and human studies [15,16]. Obesity and
hyperleptinemia caused by diet lead to impaired leptin-
induced NO and cyclic guanosine monophosphate pro-
duction in the aortic wall of rats [12] and in aortic
endothelial cells of mice [13]. Knudson et al. [14] per-
formed intracoronary leptin dose–response experiments
in anesthetized dogs and found that obese levels of
coronary plasma leptin (mean 81 ng/ml) attenuated
acetylcholine-induced coronary artery relaxation, whereas
normal physiologic levels of leptin (approximately 4 ng/ml)
had no effect. Human studies also demonstrated that the
serum leptin level is inversely associated with adenosine-
stimulated myocardial blood flow in young obese men
[15], and with forearm endothelium-dependent vasodilata-
tion (EDV) in the elderly [16]. Nevertheless, controversy
persists over whether an independent clinical association
between leptin and vascular endothelial function exists,
since the associations in the abovementioned studies were
no longer present or were attenuated after adjustment for
body mass index (BMI) in humans [15,16].
To our knowledge, no study has thus far investigated
whether leptin plays a role in vascular endothelial function
in patients with type 2 diabetes (T2D), in whom vasodila-
tion mediated by endothelium-derived NO is impaired
[17]. Therefore, the aim of the present study was to
clarify the cross-sectional association between plasma
leptin levels and vascular endothelial function, assessed
by flow-mediated dilatation (FMD) of the brachial artery
using ultrasound, in patients with T2D.
Methods
Subjects
We consecutively enrolled 171 subjects with T2D (89 men
and 82 women) who were admitted to the Diabetes Center
of the Osaka City University Hospital between January
2009 and September 2011. T2D was diagnosed on the
basis of the criteria of the American Diabetes Association
[18]. Smokers were defined as current or past smokers in
our analyses. Subjects were divided into either the lean(BMI < 25 kg/m2) or overweight (BMI 25 ≥ kg/m2) group
for analyses. Subjects with type 1 diabetes, other types of
diabetes, or renal impairment with a serum creatinine
level ≥ 1.1 mg/dL, which is the upper limit of the normal
range in our laboratory, were excluded from the present
study. All subjects provided written informed consent, and
the ethical review board of our institution approved this
study protocol.
Physical and laboratory analyses
Blood pressure was determined by the conventional cuff
method using a mercury sphygmomanometer after sub-
jects rested for at least 15 min. Blood samples were drawn
after an overnight fast and biochemical parameters were
analyzed by a standard laboratory method as previously
described [19]. Immunoreactive insulin was measured for
subjects not receiving insulin therapy (n = 108). Plasma
leptin levels were measured using enzyme-linked immuno-
sorbent assay kits (R & D Systems, Minneapolis, MN). The
minimum detectable level of leptin was 0.16 ng/mL, and
the intra- and inter-assay coefficients of variation were
3.2% and 3.5%, respectively [20].
Measurement of FMD
We measured FMD of the brachial artery according to
the International Brachial Artery Reactivity Task Force
guidelines [21] and the Japanese guidelines of the Vascular
Failure Workshop Group [22] using a novel ultrasound
system equipped with an edge-tracking system for 2D
imaging and a pulsed Doppler flow velocimeter for auto-
matic measurement (UNEXEF; Unex Co. Ltd., Nagoya,
Japan), as we [23] and others [24,25] previously described.
In brief, the diameter of the brachial artery at rest was
measured in the cubital region. Subsequently, the cuff was
inflated to 50 mmHg above systolic blood pressure (SBP)
for 5 min and then deflated. The diameter of the artery
was monitored continuously at the same point, and the
maximum dilatation from 45–60 s after deflation was
recorded. Following FMD measurement, endothelium-
independent nitroglycerin-mediated dilatation (NMD)
was also measured. After a 15-min rest for vessel recovery,
sublingual nitroglycerin (75 μg) was administered, and
the maximum dilatation of the brachial artery at the
same point was measured during at least 1 min after
the initiation of maximum dilatation. FMD and NMD were
calculated as follows: FMD or NMD (%) = (maximum
diameter – diameter at rest) × 100/diameter at rest.
Statistical analysis
Statistical analyses were performed using the JMP® 9
software (SAS Institute Inc., Cary, NC). All results
were expressed as mean ± standard deviation (SD) or
median (interquartile range) as appropriate. Student’s
t-test, Wilcoxon rank-sum test, or χ2-test was performed
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overweight groups. Simple linear regression analyses and
multiple regression analyses were performed to evaluate
the relationships between FMD and various clinical pa-
rameters including plasma leptin level. Skewed parameters
such as immunoreactive insulin, triglycerides, and plasma
leptin levels were logarithmically transformed before
regression analyses. In multiple regression analyses, FMD
was the dependent variable and plasma leptin level as
well as age; sex; BMI; waist circumference; SBP; creatinine
level; HbA1c; triglyceride level; high-density lipoprotein-
cholesterol (HDL-C) level; low-density lipoprotein-choles-
terol (LDL-C) level; smoking status; and treatment with
insulin, statins, or angiotensin-II receptor blockers or
angiotensin-converting enzyme inhibitors (ARB/ACEI)
were independent variables. A p-value < 0.05 was consid-
ered significant.
Results
Clinical characteristics of the subjects
The clinical characteristics of the lean and overweight
groups as well as the total population are shown in
Table 1. The mean ± SD for the age of all subjects was
63 ± 10 years (range, 36–86 years). Twenty subjects were
treated with dietary therapy alone, 88 with oral hypo-
glycemic agents, 39 with insulin, and 24 with a combination
of insulin and oral hypoglycemic agents. Seventy-one
subjects were treated with 3-hydroxy-3-methyl-glutaryl-
CoA reductase inhibitors (statins) and 72, with ARB/
ACEI. Overweight subjects were significantly younger
than the lean subjects. As expected, overweight subjects
had higher diastolic blood pressure (DBP), plasma insulin,
insulin resistance index by homeostasis model assessment
(HOMA-R), serum triglycerides, uric acid levels and lower
high-density lipoprotein cholesterol (HDL-C) levels than
the lean subjects. There were no significant differences
among the lean and overweight groups for frequency of
smoking, insulin use, ARB/ACEI, or statin treatment.
The median plasma leptin level for all subjects was 4.1
(2.0–8.0) ng/mL. Plasma leptin levels in the overweight
group were also significantly higher than that in the lean
group (5.9 (3.2–9.8) vs. 2.5 (1.2–4.8) ng/mL, p < 0.001).
Mean FMD for the total population was 6.8 ± 3.7% (range,
0.7–18.5), and no significant differences between over-
weight and lean subjects was found (6.5 ± 3.6% vs. 7.0 ±
3.8%, p = 0.354). Mean NMD was also not statistically
different between the two groups (15.5 ± 7.3% vs. 14.6 ±
6.6%, p = 0.424).
Association between plasma leptin levels and FMD
First, we examined the association between FMD and
plasma leptin levels or clinical risk factors for athero-
sclerosis by simple linear regression analyses for the total
population and then for lean and overweight subjectsseparately (Table 2). In all subjects, age and creatinine
level were significantly and negatively correlated with
FMD. In the lean group, none of the parameters were
significantly correlated with FMD. Age, waist-to-hip ratio
and creatinine level were negatively correlated with
FMD, and BMI was positively correlated with FMD in
the overweight group. Plasma leptin levels exhibited a
significant, positive correlation with FMD in the overweight
group, but not the lean group or the total population
(Table 2 and Figure 1). Consistent with previous reports
[23,26], NMD was negatively associated with age, waist
circumference, waist-to-hip ratio, SBP, and creatinine level
in all, lean and/or overweight subjects. However, plasma
leptin levels were not associated with NMD in either
the lean or overweight group, which is in contrast to
the relationship we found between plasma leptin levels and
FMD. In subjects not receiving insulin therapy (n = 108),
plasma leptin levels were also significantly correlated to
FMD (r = 0.337, p = 0.009), but not to NMD (r = 0.224,
p = 0.088), whereas insulin resistance assessed by HOMA-R
was not correlated to FMD (r = −0.023, p = 0.873) or NMD
(r= −0.124, p = 0.382), in the overweight group (n = 59).
In keeping with the positive correlation between plasma
leptin and FMD, subjects with plasma leptin above the
median (4.1 ng/mL) exhibited grater FMD than those
with plasma leptin below the median (7.3 ± 4.0 vs. 6.2 ±
3.2%, p = 0.042) (Figure 2). Mean NMD was not differ-
ent between subjects with plasma leptin above and below
the median (14.9 ± 7.5 and 15.2 ± 6.5%, respectively,
p = 0.799).
Since FMD could be affected by various clinical factors
and medication use for diabetes, hypertension, or dyslipid-
emia [27,28], multiple regression analyses were performed
in order to identify the impact of plasma leptin on FMD
while controlling for important confounders in all, lean
and overweight subjects, as described in the Statistical
analysis section (Table 3). Among all independent vari-
ables, only plasma leptin levels (β = 0.427, p = 0.013),
but not BMI (β = 0.107, p = 0.648) or waist circumference
(β = −0.186, p = 0.362), significantly contributed to FMD
in the overweight group. However, in the lean group,
no parameters were significantly associated with FMD
(R2 = 0.111, p = 0.885).Discussion
The present study demonstrated that plasma leptin levels
are positively related to vascular endothelial function in
overweight T2D patients, but not in lean patients. Of im-
portance, plasma leptin level was a significant contributing
factor to FMD, independent of BMI, blood pressure and
other traditional cardiovascular risk factors, in overweight
T2D patients. Our findings suggest that leptin exerts its
positive and vasodilator effect on endothelial function in
Table 1 Clinical characteristics, plasma leptin levels, FMD and NMD of all, lean, and overweight subjects
All Lean Overweight p
N (Male/female) 171 (89/82) 86 (40/46) 85 (43/42) 0.704
Age (years) 63 ± 10 66 ± 9 60 ± 11 <0.001
BMI (kg/m2) 24.8 ± 4.9 21.3 ± 2.3 28.3 ± 4.4 <0.001
Waist (cm) 87 ± 10 80 ± 7 94 ± 8 <0.001
Waist-to-hip ratio 0.93 ± 0.05 0.92 ± 0.05 0.96 ± 0.05 <0.001
SBP (mmHg) 129 ± 17 129 ± 17 130 ± 17 0.774
DBP (mmHg) 75 ± 9 73 ± 8 77 ± 9 0.006
Smoker n (%) 72 (42.1) 35 (40.7) 37 (43.5) 0.708
Insulin n (%) 63 (36.8) 37 (43.0) 26 (30.6) 0.091
ARB/ACEI n (%) 72 (42.1) 40 (46.5) 32 (37.6) 0.240
Statins n (%) 71 (41.5) 37 (43.0) 34 (40.0) 0.688
Glucose (mg/dL) 127 ± 35 129 ± 35 125 ± 35 0.524
HbA1c (NGSP,%) 8.7 ± 1.6 8.8 ± 1.7 8.6 ± 1.4 0.399
IRI (μU/mL) 6.6 (4.4–9.7) 5.3 (3.1–8.2) 8.1 (5.2–11.8) <0.001
HOMA-R 2.0 (1.3–3.0) 1.4 (0.9–2.5) 2.3 (1.4–3.4) 0.002
TG (mg/dL) 106 (81–136) 95 (72–134) 113 (91–137) 0.035
HDL-C (mg/dL) 46 ± 13 49 ± 14 43 ± 10 0.003
LDL-C (mg/dL) 109 ± 37 110 ± 38 108 ± 37 0.728
Cre (mg/dL) 0.8 ± 0.2 0.7 ± 0.2 0.8 ± 0.2 0.365
Uric acid (mg/dL) 5.7 ± 1.4 5.4 ± 1.4 5.9 ± 1.4 0.010
Leptin (ng/mL) 4.1 (2.0–8.0) 2.5 (1.2–4.8) 5.9 (3.2–9.8) <0.001
FMD (%) 6.8 ± 3.7 7.0 ± 3.8 6.5 ± 3.6 0.354
NMD (%) 15.0 ± 7.0 15.5 ± 7.3 14.6 ± 6.6 0.424
Data are expressed as mean ± SD, median (interquartile), or N (%) as appropriate. BMI, body mass index; Waist, waist circumference; SBP, systolic blood pressure;
DBP, diastolic blood pressure; smoker, past and current smokers; insulin, frequency of subjects treated with insulin; ARB/ACEI, frequency of subjects treated with
angiotensin II receptor antagonists or ACE inhibitors; statins; frequency of subjects treated with stains; IRI, immunoreactive insulin; HOMA-R, insulin resistance
index by homeostasis model assessment; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Cre, serum
creatinine; FMD, endothelium-dependent, flow-mediated dilatation of the brachial artery; NMD, endothelium-independent, nitroglycerin-mediated dilatation of the
brachial artery.
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cardiovascular diseases.
A number of clinical studies have investigated the asso-
ciation between plasma leptin levels and vascular endothe-
lial function [16,29-31]. Plasma leptin levels were reported
to be negatively associated with EDV measured by forearm
plethysmography in the elderly subjects [16], and with
FMD of the brachial artery in patients with nonalcoholic
fatty disease [29] and polycystic ovarian syndrome [30].
However, the association of plasma leptin with vascular
endothelial function was not independent of the other
variables including BMI in these studies. Plasma leptin-to
adiponectin ratio was also shown to be negatively associ-
ated with FMD in healthy elderly subjects [31]. In the
other studies, plasma leptin levels were not associated
with FMD of the brachial artery [32-37]. FMD was evalu-
ated after weight reduction by low-calorie diet for obese
subjects in several studies [38-41]. Increased FMD after
weight loss was negatively [38], positively [39], or not[40,41] associated with change in plasma leptin levels.
These previous cross-sectional and interventional studies
demonstrate inconsistent results on the relationship be-
tween leptin and endothelial function, possibly because
the study subjects or the method used to estimate endo-
thelial function differs. The findings of our study contrast
with those of these previous studies in that the association
of leptin levels with FMD was independent of confound-
ing cardiovascular risk factors such as age, BMI, SBP, and
lipids in overweight T2D patients. In addition, moderately
elevated plasma leptin levels unexpectedly exhibited a
positive relation with FMD in overweight patients with
T2D in this study. These patients are also generally at a
high risk for atherosclerosis and cardiovascular disease.
Functional leptin receptors are expressed in vascular
endothelium [9]. Several experimental studies showed that
acutely administered leptin induces endothelium-dependent
vasorelaxation by stimulating the release of endothelial NO
or the endothelium-derived hyperpolarizing factor (EDHF)
Table 2 Correlations between FMD, NMD, and clinical variables in subjects with type 2 diabetes
FMD NMD
All subjects Lean Overweight All subjects Lean Overweight
r p r p r p r p r p r p
Age −0.175 0.022 −0.007 0.948 −0.371 <0.001 −0.425 <0.001 −0.382 <0.001 −0.545 <0.001
BMI 0.101 0.191 0.034 0.756 0.330 0.002 −0.044 0.572 −0.192 0.077 0.111 0.313
Waist 0.014 0.852 0.005 0.967 0.155 0.159 −0.169 0.028 −0.287 0.008 −0.051 0.648
Waist-to-hip ratio −0.134 0.083 0.067 0.545 −0.285 0.009 −0.220 0.004 −0.200 0.067 −0.225 0.040
SBP −0.123 0.110 −0.054 0.622 −0.193 0.076 −0.315 <0.001 −0.405 <0.001 −0.213 0.051
DBP 0.032 0.676 0.172 0.113 −0.059 0.593 −0.005 0.946 −0.053 0.627 0.065 0.555
Cre −0.168 0.028 −0.090 0.409 −0.236 0.030 −0.161 0.036 −0.084 0.441 −0.235 0.031
Glucose −0.050 0.519 −0.117 0.284 0.015 0.893 −0.069 0.370 −0.033 0.765 −0.118 0.284
HbA1c −0.147 0.055 −0.174 0.108 −0.125 0.253 0.012 0.875 0.029 0.788 −0.021 0.846
Log [IRI] −0.049 0.622 −0.009 0.954 0.035 0.799 −0.069 0.487 −0.068 0.642 −0.019 0.892
Log [HOMA-R] −0.047 0.639 0.007 0.961 0.013 0.925 −0.125 0.206 −0.140 0.338 −0.071 0.608
Log [TG] 0.025 0.746 0.024 0.829 0.056 0.614 0.024 0.756 0.082 0.455 −0.037 0.739
HDL-C 0.025 0.748 −0.016 0.881 0.045 0.682 −0.098 0.203 −0.116 0.286 −0.115 0.295
LDL-C −0.004 0.962 −0.108 0.324 0.105 0.339 0.135 0.079 0.176 0.106 0.085 0.442
Uric acid 0.069 0.369 0.024 0.827 0.147 0.179 −0.016 0.838 0.018 0.873 −0.027 0.809
Log [Leptin] 0.136 0.077 0.107 0.329 0.290 0.007 −0.0003 0.997 −0.0001 0.999 0.070 0.522
r, correlation coefficient by simple regression analysis. Abbreviations are the same as Table 1.
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Endothelium-independent vasodilation by leptin was also
identified in the saphenous vein and internal mammary
artery ex vivo in humans with coronary artery disease [44].
A direct vasodilator effect of acute leptin infusion has also
been investigated in several human studies. Nakagawa
et al. [10] reported forearm vasodilatation by intra-arterial
infusion of leptin, and coronary artery vasodilation by
intra-coronary leptin infusion in a separate study [11]. The
leptin-induced vasodilatation was independent of NO and
possible involvement of other vasoactive agents such as
the EDHF or prostacyclin was suggested in those human
studies [10,11]. Brook et al. [45] demonstrated that bra-
chial FMD increased 2 hours following subcutaneous
injection of recombinant human leptin without altering
blood pressure in non-obese adults. These in vitro and
in vivo data indicate a direct vasodilator effect of leptin on
the endothelium through endothelial NO or other factors,
and this could support our finding, at least in part, that
an independent and positive association exists between
plasma leptin levels and FMD in overweight subjects.
On the other hand, a number of studies have shown
that leptin regulates the sympathetic nervous system,
endothelin-1 production, and renin-angiotensin system
[4,46], all of which contribute to vasoconstriction and
may counteract the depressor effect of leptin on vascular
function. Moreover, a large number of studies have indi-
cated that leptin regulates immune function and cytokine
secretion, upregulates C-reactive protein production, andincreases oxidative stress in endothelial cells, all of which
promote the pathophysiology of atherogenesis includ-
ing endothelial dysfunction [1,4,47,48]. Indeed, obesity
or long-term hyperleptinemia was shown to reduce NO
bioavailability of the aortic endothelium mice [13] and rats
[12], and to attenuate NO-dependent vasodilation of the
coronary artery in dogs [14]. Schinzari et al. [49] demon-
strated in human study that leptin infusion enhanced EDV
in lean subjects, but not in patients with obesity-related
MetS. High leptin concentrations were also reported to
be associated with impaired EDV measured by forearm
plethysmography [16] and inversely with adenosine-
stimulated coronary blood flow [15] in human subjects,
but those associations were not independent of BMI and/
or insulin levels. These experimental and clinical studies
indicate that the NO-dependent vasodilatory effects of lep-
tin become impaired, and by this mechanism, leptin may
contribute to endothelial dysfunction and the progression
of atherosclerosis in patients with obesity and/or MetS.
These studies imply that the selective leptin resistance seen
in obesity may not be limited to appetite and body weight
control, but may involve the hemodynamic actions of
leptin, thus leading to the pro-atherogenic effects of leptin
on vascularture [50]. However, to date, no previous study
has demonstrated an independent association of leptin
with brachial artery FMD assessed by ultrasound, in
human subjects with obesity and/or MetS.
To our knowledge, this is the first study to explore the
association of leptin with vascular endothelial function
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Figure 1 Association of plasma leptin levels with the
flow-mediated dilatation (FMD) of the brachial artery in (a) all
subjects, (b) the lean group, or (c) the overweight group.
Plasma leptin levels were positively correlated with FMD in the
overweight group, but not the lean group or the total population.
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positive association between plasma leptin levels and
FMD in overweight (BMI ≥ 25 kg/m2), but not lean sub-
jects, even after adjustment for other confounders includ-
ing age, BMI, SBP, HbA1c, and lipid levels. The positiveassociation between plasma leptin levels and FMD in
patients with diabetes is contrary to previous studies
that show an association between hyperleptinemia and
impaired endothelial function in patients with obesity
and/or MetS. There are several possible explanations
for this discrepancy. First, the degree of obesity in our
Japanese patients was much less than that of the studies
performed in European countries, which demonstrated
a resistance to leptin-induced vasoreactivity in human
subjects with obesity or MetS [15,49]. BMI and plasma
leptin levels were 33.6 kg/m2 and 10.3 ng/mL, respectively,
in obese subjects from the study by Sundell and colleagues
[15], and 38 kg/m2 and 21.2 ng/mL, respectively, in sub-
jects with MetS in the study by Schinzari and colleagues
[49]. These BMI and leptin levels are much higher than
those of our overweight subjects (BMI, 28.4 kg/m2; leptin
levels, 6.0 ng/mL). Moreover, the plasma leptin levels
of our overweight subjects were similar to those of the
healthy [15] and control subjects [49], at 4.3 ng/mL and
8.7 ng/mL, respectively, in two studies from Europe.
Therefore, the vasodilator effect of leptin could have still
been activated in our overweight subjects because their
leptin levels were not very hyperleptinemic. In addition,
plasma leptin did not exhibit a significant association with
FMD in our lean subjects. This could be due to their low
leptin levels (2.5 ng/mL), at which leptin has not been
found to exert significant vasodilation in Japanese subjects
[10]. Second, forearm plethysmography reflects endothe-
lial function of the resistance artery mediated mainly by
the EDHF, whereas FMD reflects the conduit artery by
NO [9]. An animal study showed that even if the endo-
thelial NO synthase-derived NO production is impaired
or absent, leptin can induce neuronal NO synthase in the
endothelium to maintain endothelium dependent-vasore-
laxation in a mouse model of obesity with hyperlepti-
neima or angiotensin-II-induced vascular dysfunction [43].
Therefore, in this study, NO-mediated vasodilation
assessed with FMD of the brachial artery was observed
in overweight diabetic subjects with mildly elevated
plasma leptin levels. Third, overweight subjects in this
study were significantly younger than the lean subjects.
Endothelial dysfunction assessed by FMD is recognized
as an early marker of vascular damage, contributing to the
initiation and progression of atherosclerosis [7]. Although
intima-media thickness of the carotid artery did not
significantly differ between groups (lean, 1.06 ± 0.60 mm;
overweight, 0.99 ± 0.45 mm; p = 0.456), it could be specu-
lated that the overweight subjects in our study had less
advanced atherosclerosis, and were thus able to respond
to the vasodilator effect of moderately elevated plasma
leptin levels at the time of FMD measurement.
Our results further demonstrated that plasma leptin
levels were also independently and positively associated
with NMD in both lean and overweight subjects and
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Figure 2 Comparison of FMD (a) or NMD (b) between high and low plasma leptin groups. *, p < 0.05. The subjects with higher leptin levels
exhibited significantly higher FMD, but not NMD, than subjects with lower leptin levels.
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other confounders including age, obesity, BP, and lipids.
The vasodilator response to exogenous NO reflects vascu-
lar smooth muscle function and is reported to be impaired
independently of endothelial dysfunction in subjects at
risk for atherosclerosis [26]. Apart from the endothelium,
leptin was also shown to directly target vascular smooth
muscle cells via NO-dependent [51] and NO/endothelium
independent [44] manner. Thus, the correlation between
leptin and NMD in both lean and overweight subjects
may reflect the smooth muscle-dependent vasodilator
effect of leptin, which can be observed even in lean
T2D patients with low plasma leptin levels.Table 3 Multivariate analyses of the determinants for FMD an
FMD
All subjects Lean Overw
β p β p β
Age (years) −0.178 0.081 −0.058 0.692 −0.246
Sex (male = 1) −0.014 0.917 −0.195 0.346 0.167
BMI (kg/m2) 0.035 0.860 −0.037 0.871 0.107
Waist (cm) −0.150 0.403 0.048 0.807 −0.186
SBP (mmHg) −0.094 0.271 −0.064 0.643 −0.220
Cre (mg/dL) −0.046 0.644 0.054 0.732 −0.031
HbA1c (%) −0.186 0.034 −0.155 0.314 −0.138
Log [TG (mg/dL)] 0.000 0.999 −0.035 0.836 0.110
HDL-C (md/dL) 0.097 0.325 0.079 0.625 0.046
LDL-C (mg/dL) −0.051 0.554 −0.107 0.432 0.014
Smoking (yes = 1) −0.080 0.378 −0.053 0.702 −0.049
Insulin (yes = 1) −0.050 0.572 −0.175 0.236 0.056
Statins (yes = 1) 0.008 0.915 0.037 0.768 −0.035
ARB/ACEI (yes = 1) −0.104 0.209 −0.069 0.576 −0.171
Log [Leptin (ng/mL)] 0.158 0.246 0.038 0.859 0.427
R2 0.132 0.094 0.111 0.885 0.310
β, standard correlation coefficient by multiple regression analysis; R2, multiple coeffThere were a few limitations of our study. First, this was
a cross-sectional study; therefore, a causal relationship
between plasma leptin and FMD cannot be clarified.
Second, the patients with T2D in this study were receiving
various anti-atherogenic drug interventions such as anti-
hypertensive agents, statins and insulin therapy that
can exert considerable effects on FMD of the brachial
artery and related atherosclerotic risk factors. To minimize
the effect of such treatments, we adjusted for patient treat-
ment status in our multivariate analyses. Third, our over-
weight subjects were significantly younger than the lean
subjects. A positive relationship between BMI and FMD
was also found in the univariate analysis. Since all potentiald NMD in subjects with type 2 diabetes
NMD
eight All subjects Lean Overweight
p β p β p β p
0.096 −0.453 <0.001 −0.149 0.227 −0.724 <0.001
0.379 0.116 0.310 0.214 0.217 0.028 0.863
0.648 −0.150 0.374 −0.250 0.196 −0.346 0.089
0.362 −0.366 0.018 −0.237 0.157 −0.131 0.457
0.069 −0.241 0.001 −0.378 0.002 −0.203 0.053
0.824 −0.076 0.375 0.010 0.941 −0.073 0.548
0.207 −0.009 0.907 0.011 0.931 −0.006 0.953
0.355 −0.098 0.231 −0.057 0.691 −0.096 0.350
0.703 −0.125 0.134 −0.078 0.564 −0.233 0.027
0.912 −0.050 0.494 0.045 0.694 −0.189 0.087
0.712 0.026 0.732 0.064 0.580 −0.039 0.730
0.646 −0.073 0.338 −0.155 0.210 −0.066 0.530
0.747 −0.030 0.652 0.008 0.942 −0.032 0.727
0.151 −0.040 0.572 −0.020 0.846 −0.019 0.851
0.013 0.341 0.004 0.462 0.011 0.318 0.031
0.025 0.372 <0.001 0.376 0.002 0.485 <0.001
icients of determination. Abbreviations are the same as Table 1.
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the consecutive inclusion of our subjects, factors including
age and BMI were adjusted for and the independent
association of leptin was confirmed in the multivariate
analyses. Fourth, no healthy controls were used to com-
pare our findings, and we could not confirm that FMD
was impaired in our study population of T2D patients.
Last, this study included a very low number of morbidly
obese patients with a BMI ≥ 30 kg/m2 (n = 15, 8.8%); thus,
our results are only applicable to normal or overweight
T2D patients. Leptin could contribute differently to FMD
in morbidly obese patients with more severe leptin re-
sistance and hyperleptinemia than overweight subjects
[15,49,52].
Further studies with a larger population that includes
T2D patients with a wide range of BMI are required to
validate these findings. Furthermore, prospective and
interventional studies assessing changes in both plasma
leptin levels and FMD are warranted to clarify whether
plasma leptin levels are predictive of vascular endothelial
function in patients with obesity and T2D.
Conclusions
Our data demonstrate that the plasma leptin level is an
independent determinant of better FMD of the brachial
artery in overweight, but not lean, patients with T2D. The
present study provides clinical evidence that leptin is asso-
ciated with vascular endothelial function in T2D patients
with moderate obesity.
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